

Alexander D Douglas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4986223/publications.pdf>

Version: 2024-02-01

58
papers

13,701
citations

94269

37
h-index

133063

59
g-index

67
all docs

67
docs citations

67
times ranked

19066
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
4	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
5	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
6	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
7	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
8	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
9	The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. <i>Nature Communications</i> , 2011, 2, 601.	5.8	233
10	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
11	ChAd63-MVA vectorized Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. <i>Molecular Therapy</i> , 2012, 20, 2355-2368.	3.7	196
12	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV, the</i> , 2021, 8, e474-e485.	2.1	190
13	Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. <i>Nature</i> , 2014, 515, 427-430.	13.7	180
14	A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. <i>Cell Host and Microbe</i> , 2015, 17, 130-139.	5.1	178
15	Neutralization of <i>Plasmodium falciparum</i> Merozoites by Antibodies against PfRH5. <i>Journal of Immunology</i> , 2014, 192, 245-258.	0.4	132
16	Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing Combinations of Antibodies against PfRH5 and Other Merozoite Antigens. <i>PLoS Pathogens</i> , 2012, 8, e1002991.	2.1	114
17	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against <i>Plasmodium falciparum</i> infection in Kenyan adults. <i>Science Translational Medicine</i> , 2015, 7, 286re5.	5.8	113
18	Evaluation of the Efficacy of ChAd63-MVA Vectorized Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. <i>Journal of Infectious Diseases</i> , 2015, 211, 1076-1086.	1.9	110

#	ARTICLE	IF	CITATIONS
19	Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. <i>JCI Insight</i> , 2017, 2, .	2.3	109
20	Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies. <i>Cell</i> , 2019, 178, 216-228.e21.	13.5	107
21	Demonstration of the Blood-Stage <i>Plasmodium falciparum</i> Controlled Human Malaria Infection Model to Assess Efficacy of the <i>P. falciparum</i> Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. <i>Journal of Infectious Diseases</i> , 2016, 213, 1743-1751.	1.9	95
22	Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. <i>PLoS ONE</i> , 2011, 6, e22271.	1.1	84
23	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved <i>P. falciparum</i> Parasites Administered by Needle and Syringe. <i>PLoS ONE</i> , 2013, 8, e65960.	1.1	80
24	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
25	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021, 2, 701-719.e19.	2.2	73
26	Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. <i>Molecular Therapy</i> , 2014, 22, 2142-2154.	3.7	68
27	Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against <i>Plasmodium falciparum</i> MSP1. <i>Vaccine</i> , 2010, 28, 7167-7178.	1.7	62
28	The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. <i>Journal of Immunology</i> , 2011, 187, 2602-2616.	0.4	55
29	Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal α -C-tag TM . <i>International Journal for Parasitology</i> , 2017, 47, 435-446.	1.3	55
30	Production of full-length soluble <i>Plasmodium falciparum</i> RH5 protein vaccine using a <i>Drosophila melanogaster</i> Schneider 2 stable cell line system. <i>Scientific Reports</i> , 2016, 6, 30357.	1.6	54
31	Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 340-345.	1.9	53
32	Production, quality control, stability, and potency of cGMP-produced <i>Plasmodium falciparum</i> RH5.1 protein vaccine expressed in <i>Drosophila</i> S2 cells. <i>Npj Vaccines</i> , 2018, 3, 32.	2.9	53
33	A defined mechanistic correlate of protection against <i>Plasmodium falciparum</i> malaria in non-human primates. <i>Nature Communications</i> , 2019, 10, 1953.	5.8	51
34	Blood-stage Challenge for Malaria Vaccine Efficacy Trials: A Pilot Study with Discussion of Safety and Potential Value. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 878-883.	0.6	49
35	Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of <i>Plasmodium Vivax</i> . <i>Frontiers in Immunology</i> , 2015, 6, 348.	2.2	44
36	A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006870.	1.3	40

#	ARTICLE	IF	CITATIONS
37	Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. <i>Malaria Journal</i> , 2015, 14, 33.	0.8	39
38	Manufacturing a chimpanzee adenovirusâ€‘vectored SARSâ€‘CoVâ€‘2 vaccine to meet global needs. <i>Biotechnology and Bioengineering</i> , 2022, 119, 48-58.	1.7	38
39	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
40	Substantially Reduced Pre-patent Parasite Multiplication Rates Are Associated With Naturally Acquired Immunity to <i>Plasmodium falciparum</i> . <i>Journal of Infectious Diseases</i> , 2011, 203, 1337-1340.	1.9	36
41	The utility of <i>Plasmodium berghei</i> as a rodent model for anti-merozoite malaria vaccine assessment. <i>Scientific Reports</i> , 2013, 3, 1706.	1.6	36
42	Challenges of assessing the clinical efficacy of asexual blood-stage <i>Plasmodium falciparum</i> malaria vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1831-1840.	1.4	34
43	Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines. <i>Journal of Immunology</i> , 2016, 197, 1242-1251.	0.4	34
44	Functional Comparison of Blood-Stage <i>Plasmodium falciparum</i> Malaria Vaccine Candidate Antigens. <i>Frontiers in Immunology</i> , 2019, 10, 1254.	2.2	31
45	Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components. <i>Vaccine</i> , 2019, 37, 6951-6961.	1.7	31
46	External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. <i>PLoS ONE</i> , 2014, 9, e97398.	1.1	28
47	Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 878-83.	0.6	27
48	Standardization of the antibody-dependent respiratory burst assay with human neutrophils and <i>Plasmodium falciparum</i> malaria. <i>Scientific Reports</i> , 2015, 5, 14081.	1.6	22
49	CD8+ T Cellâ€‘Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma. <i>Journal of Immunology</i> , 2014, 192, 224-233.	0.4	21
50	Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on <i>Plasmodium yoelii</i> malaria challenge outcome. <i>Journal of Leukocyte Biology</i> , 2013, 95, 369-382.	1.5	18
51	Immunological considerations for SARS-CoV-2 human challenge studies. <i>Nature Reviews Immunology</i> , 2020, 20, 715-716.	10.6	13
52	Evaluation of Point-of-care Activated Partial Thromboplastin Time Testing by Comparison to Laboratory-based Assay for Control of Intravenous Heparin. <i>Angiology</i> , 2009, 60, 358-361.	0.8	8
53	Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations. <i>Vaccines</i> , 2021, 9, 1249.	2.1	8
54	The Difficult Venous Ulcer: Case Series of 177 Ulcers Referred for Vascular Surgical Opinion following Failure of Conservative Management. <i>Angiology</i> , 2009, 60, 492-495.	0.8	4

#	ARTICLE	IF	CITATIONS
55	PfRH5 vaccine efficacy against heterologous strain blood-stage Plasmodium falciparum. Lancet, The, 2014, 383, S43.	6.3	2
56	Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation. Scientific Reports, 2021, 11, 20877.	1.6	2
57	Clinical Evaluation Of New Viral Vectored Vaccines Targeting The Plasmodium Falciparum Blood-Stage Antigens; Msp1 And Ama1. Journal of Infection, 2011, 63, 492-493.	1.7	0
58	Subunit Blood-Stage Malaria Vaccines. , 2017, , 211-238.		0